Financial News

BioNTech 1Q Revenues Tumble

Expands pipeline and alliances amid plummeting COVID-19 vaccine sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech 1Q Revenue: €1.3 billion (revenue was €6.4 billion 1Q22) 1Q Earnings: €502.2 million (earnings were €3.7 billion 1Q22) Comments: Results in the quarter impacted by lower commercial revenues from the supply and sales of the company’s COVID-19 vaccines worldwide. For the COVID-19 vaccine franchise, the company plans to focus on vaccine adaptation for the fall season and advancing next generation vaccine candidates and combinations.   BioNTech and partner OncoC4 plan to start a Phase ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters